A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alan Pestronk, MD
Washington University School of Medicine
Principal Investigator - Heather Lau, MD
NYU Langone Health
Principal Investigator - Perry Shieh, MD
University of California, Los Angeles
Principal Investigator - Yoseph Caraco, MD
Hadassah University Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hadassah University Hospital
Jerusalem, Israel
- Ucla Medical Center
Los Angeles, California, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- New York University School of Medicine
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2012
- Primary completion
- 30 Nov 2013
- Completion
- 30 Nov 2013
- Last update posted
- 16 Jun 2016
- Registered enrollment
- 46
- Registry id
- NCT01517880
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.